Wednesday - June 4, 2025
UT-MD Anderson Cancer Center: ASCO - Triple Therapy Regimen Significantly Improves Survival in BRAF V600E-mutated Metastatic Colorectal Cancer
May 31, 2025
HOUSTON, Texas, May 31 -- The University of Texas MD Anderson Cancer Center issued the following news release:

* * *

ASCO: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

* Approximately 8 to 12% of patients with colorectal cancer have BRAF mutations

* Treatment with the triplet combination of drugs - encorafenib, cetuximab and chemotherapy - helped patients live longer and kept cancer f . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products